Diphenhydramine Market

Executive Summary

Diphenhydramine Market was valued at US $258.32 million in 2021 and is projected to grow at 10.12% CAGR over the forecast period to reach US $460.53 million by 2027. Diphenhydramine Market represented US $45.28 million opportunity over 2019-2021 and estimated to create US $202.21 million opportunity in 2027 over 2021.

Diphenhydramine from Consainsights analyses the Diphenhydramine Market in the Life Sciences industry over the forecast period to 2027.

Diphenhydramine research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Diphenhydramine segmentation includes Dosage Forms, Application and Geography.

Based on the Dosage Forms, the Diphenhydramine analysis covers Tablets, Injection, Powder, Syrups.

In Dosage Forms segment, Tablets segment has highest cagr growth of 8.94%.

Based on the Application, the Diphenhydramine analysis covers Allergies, Insomnia, Cold, Nausea, Other Applications.

In Application segment, Allergies segment has highest cagr growth of 8.94%.

Based on the region, the Diphenhydramine analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Cardinal Health, Pharmaceutical Assocaites, Bayer Healthcare, Pfizer Inc., Johnson and Johnson, Cigna, Remedy Labs, Wan Bury and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Dosage Forms

Introduction

In 2021, Tablets segment has the highest revenue of US $123.79 million and is expected to grow at CAGR of 8.94% by 2027 Tablets segment has highest cagr growth of 8.94%.

Tablets

Tablets segment was valued at US $102.09 million in 2019 and is projected to grow at 8.94% CAGR over the forecast period to reach US $220.70 million by 2027. Tablets segment represented US $21.70 million opportunity over 2019-2021 and estimated to create US $96.90 million opportunity in 2027 over 2021.

Injection

Injection segment was valued at US $59.99 million in 2019 and is projected to grow at 8.94% CAGR over the forecast period to reach US $129.67 million by 2027. Injection segment represented US $12.75 million opportunity over 2019-2021 and estimated to create US $56.94 million opportunity in 2027 over 2021.

Powder

Powder segment was valued at US $29.48 million in 2019 and is projected to grow at 8.94% CAGR over the forecast period to reach US $63.74 million by 2027. Powder segment represented US $6.27 million opportunity over 2019-2021 and estimated to create US $27.99 million opportunity in 2027 over 2021.

Syrups

Syrups segment was valued at US $21.48 million in 2019 and is projected to grow at 8.94% CAGR over the forecast period to reach US $46.43 million by 2027. Syrups segment represented US $4.57 million opportunity over 2019-2021 and estimated to create US $20.39 million opportunity in 2027 over 2021.

Application

Introduction

In 2021, Allergies segment has the highest revenue of US $100.88 million and is expected to grow at CAGR of 8.94% by 2027 Allergies segment has highest cagr growth of 8.94%.

Allergies

Allergies segment was valued at US $83.20 million in 2019 and is projected to grow at 8.94% CAGR over the forecast period to reach US $179.85 million by 2027. Allergies segment represented US $17.68 million opportunity over 2019-2021 and estimated to create US $78.97 million opportunity in 2027 over 2021.

Insomnia

Insomnia segment was valued at US $47.24 million in 2019 and is projected to grow at 8.94% CAGR over the forecast period to reach US $102.11 million by 2027. Insomnia segment represented US $10.04 million opportunity over 2019-2021 and estimated to create US $44.83 million opportunity in 2027 over 2021.

Cold

Cold segment was valued at US $36.14 million in 2019 and is projected to grow at 8.94% CAGR over the forecast period to reach US $78.13 million by 2027. Cold segment represented US $7.68 million opportunity over 2019-2021 and estimated to create US $34.30 million opportunity in 2027 over 2021.

Nausea

Nausea segment was valued at US $26.18 million in 2019 and is projected to grow at 8.94% CAGR over the forecast period to reach US $56.60 million by 2027. Nausea segment represented US $5.57 million opportunity over 2019-2021 and estimated to create US $24.85 million opportunity in 2027 over 2021.

Other Applications

Other Applications segment was valued at US $20.28 million in 2019 and is projected to grow at 8.94% CAGR over the forecast period to reach US $43.85 million by 2027. Other Applications segment represented US $4.31 million opportunity over 2019-2021 and estimated to create US $19.25 million opportunity in 2027 over 2021.